Stock Scorecard



Stock Summary for VYNE Therapeutics Inc (VYNE) - $0.59 as of 3/14/2026 10:23:09 AM EST

Total Score

12 out of 30

Safety Score

8 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VYNE

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VYNE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VYNE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VYNE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VYNE (8 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for VYNE

VYNE SEC Filings - Vyne Therapeutics Inc 10-K, 10-Q, 8-K Forms 3/14/2026 6:52:00 AM
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance 3/14/2026 12:39:00 AM
Nasdaq grants VYNE Therapeutics (VYNE) more time to fix sub-$1 share price 3/12/2026 2:52:00 PM
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance 3/12/2026 12:52:00 AM
VYNE Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard 3/11/2026 9:52:00 PM
Vyne Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview 3/2/2026 1:57:00 PM
VYNE Earning Date, Earning Analysis and Earning Prediction 3/2/2026 6:52:00 AM
VYNE Stock News Today | Earnings, Events & Price Alerts 2/28/2026 10:52:00 AM
VYNE: Losses narrowed in 2025 as the company pivots to a merger with Yarrow and exits key R&D programs 2/27/2026 12:52:00 PM
VYNE Therapeutics Inc. SEC 10-K Report 2/27/2026 12:52:00 PM

Financial Details for VYNE

Company Overview

Ticker VYNE
Company Name VYNE Therapeutics Inc
Country N/A
Description VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 0.59
Price 4 Years Ago 2.70
Last Day Price Updated 3/14/2026 10:23:09 AM EST
Last Day Volume 244,987
Average Daily Volume 329,241
52-Week High 1.99
52-Week Low 0.28
Last Price to 52 Week Low 110.71%

Valuation Measures

Trailing PE N/A
Industry PE 28.82
Sector PE 98.23
5-Year Average PE -1.17
Free Cash Flow Ratio 0.82
Industry Free Cash Flow Ratio 9.16
Sector Free Cash Flow Ratio 25.46
Current Ratio Most Recent Quarter 12.53
Total Cash Per Share 0.72
Book Value Per Share Most Recent Quarter 0.83
Price to Book Ratio 0.71
Industry Price to Book Ratio 71.63
Sector Price to Book Ratio 36.25
Price to Sales Ratio Twelve Trailing Months 34.57
Industry Price to Sales Ratio Twelve Trailing Months 20.21
Sector Price to Sales Ratio Twelve Trailing Months 8.03
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 33,323,200
Market Capitalization 19,660,688
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 33.52%
Reported EPS 12 Trailing Months -0.63
Reported EPS Past Year -0.62
Reported EPS Prior Year -0.94
Net Income Twelve Trailing Months -26,483,000
Net Income Past Year -26,483,000
Net Income Prior Year -39,834,000
Quarterly Revenue Growth YOY 54.80%
5-Year Revenue Growth -51.39%
Operating Margin Twelve Trailing Months -4,015.00%

Balance Sheet

Total Cash Most Recent Quarter 24,027,000
Total Cash Past Year 24,027,000
Total Cash Prior Year 19,926,000
Net Cash Position Most Recent Quarter 24,027,000
Net Cash Position Past Year 24,027,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 27,765,000
Total Stockholder Equity Prior Year 52,086,000
Total Stockholder Equity Most Recent Quarter 27,765,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -33,124,000
Free Cash Flow Per Share Twelve Trailing Months -0.99
Free Cash Flow Past Year -33,124,000
Free Cash Flow Prior Year -34,089,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.01
MACD Signal 0.01
20-Day Bollinger Lower Band 0.32
20-Day Bollinger Middle Band 0.52
20-Day Bollinger Upper Band 0.72
Beta 2.03
RSI 59.13
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 3/21/2026 10:11:59 AM EST